SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Form
4
Filing Date
Mar 2, 2023
Document Date
Mar 1, 2023
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.
Filer
Gergen Mark J